Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC

MELBOURNE, Australia, June 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRC...

2023-06-27 03:51 1875

Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023

HANGZHOU and SHAOXING, China, June 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated interferon (PEG-IFN) and entecavir (ETV) in chronic hepatitis B (...

2023-06-26 08:10 2627

Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China

ROCKVILLE, Md. and SUZHOU, China, June 26, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...

2023-06-26 08:00 3158

Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693

Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to treat MDR/XDR gram-negative bacterial infections Company returns Greater China rights to Qpex Biopharma of beta-lactamase inhibitor QPX7728-based products Company to receive ~$24M upfront cash payme...

2023-06-26 07:30 2288

Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment New data show more robust and persistent anti-HBs titers following vaccination with VBI's 3-antigen prevention vac...

2023-06-25 20:00 2878

Sciwind Biosciences to Highlight Positive Clinical Data for GLP-1 Peptide Agonist Ecnoglutide (XW003) at the American Diabetes Association (ADA) 83rd Annual Conference

* Results from three clinical studies show ecnoglutide to be safe and well-tolerated, and demonstrate robust therapeutic effects in overweight/obese and type 2 diabetes patients * On-going Phase 3 clinical trials in Chinese patients with type 2 diabetes and obesity have achieved target enroll...

2023-06-24 10:00 4187

Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics

Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures Unique Click-to-Release platform enables on-target activation of antibody-drug conjugates (ADCs) and immunomodulators, as well as off-target ...

2023-06-22 21:53 2528

Polyplastics Announces Commercial Availability of DURACON (R) POM PM Series for Medical Industry

TOKYO, June 22, 2023 /PRNewswire/ -- The Polyplastics Group is pleased to announce the commercial availability of its DURACON (R) POM (Polyoxymethylene/Acetal) PM Series for medical applications. The company will supply materials to all global regions, includingAsia such as China, India, Europe,...

2023-06-22 13:00 2362

Teikoku Pharma granted FDA Fast Track Designation for TPU-006, a Novel 4-day Dexmedetomidine Transdermal System for Post Operative Pain Management

SAN JOSE, June 21, 2023 /PRNewswire/ -- Teikoku Pharma USA, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for TPU-006 in managing postoperative pain. TPU-006 is an investigational 4-day dexmedetomidine transdermal...

2023-06-21 19:05 1813

Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical

MELBOURNE, Australia, June 21, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. Lightpoint Medical is aUnited Kingdom-based medical device...

2023-06-21 17:32 2721

Novo Nordisk Global Business Services earns the Best Place To Work certificate in India for 2023

BENGALURU, India, June 21, 2023 /PRNewswire/ -- Novo Nordisk Global Business Services (GBS) has been recently awarded as a best place to work inIndia by Best Places to Work – an international HR certification program. The program provides employers in different countries the opportunity to learn ...

2023-06-21 17:07 2170

Everest Medicines' Partner Calliditas Therapeutics Makes Data Presentations on Nefecon at European Renal Association - European Dialysis and Transplant Association Congress (ERA-EDTA )

SHANGHAI, June 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that its partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") made presentations on data from the NeflgArd Phase 3 Study at the European Renal...

2023-06-21 08:15 4157

Telix Urology Innovation Showcase to be held at The Yale Club, New York City

MELBOURNE, Australia and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an outline agenda for the Company's briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.3...

2023-06-21 06:31 2438

Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 19, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Company"; stock code: 2257, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the adv...

2023-06-19 21:29 3673

Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients

ALHAMBRA, Calif., June 19, 2023 /PRNewswire/ -- Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, today announced topline data from the company's Phase1b clinical trial for AG-80308, a first-in-class, formyl peptide re...

2023-06-19 16:00 1457

Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients

- Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of ECP in heart transplant patients reinforce its use as a treatment for heart transplant rejection and prevention of rejection1 - DUBLIN, June 19, 2023 /PR...

2023-06-19 06:30 2343

The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of Treating Respiratory Viral Infections with Single Drug

- Professor Heungjeong Woo of Hallym University College of Medicine, announced the result of Xafty's clinical study at Emerging Science Session of the American Society for Microbiology (ASM) Microbe 2023 - Dr. Jo White evaluated Xafty's clinical results as "The birth of Penicillin of Antivirals"...

2023-06-18 03:30 3685

The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of Treating Respiratory Viral Infections with Single Drug

Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million

HONG KONG, June 16, 2023 /PRNewswire/ -- On June 11, 2023, Viva Biotech Holdings Group (1873.HK) announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised nearlyUS$ 150 million through the transfer of approximately 24% of its equity interest to Temasek,...

2023-06-16 14:20 5544

Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer

SHANGHAI, June 16, 2023 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, today announced that Dr.Mike Berry has been appointed Chief Techno...

2023-06-16 07:45 2516

Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall

* Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaign * Novavax shared data demonstrating that its XBB.1.5 COVID vaccine candidate induces functional immu...

2023-06-16 06:05 2562

1 ... 28 29 303132 33 34 ... 181